^
    Back
    Association details:
    Biomarker:EGFR exon 20 insertion
    Cancer:Non Small Cell Lung Cancer
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ELCC 2022
    Title:

    EGFR exon 20 insertion mutations in patients with locally advanced or metastatic NSCLC in the German prospective, CRISP Registry real-world cohort (AIO-TRK-0315)

    Published date:
    03/23/2022
    Excerpt:
    Most pts (75%) received platin-based combination chemotherapy (ctx) pembrolizumab in 1st-line. Median PFS and OS from start of 1st-line were 8.4 [95%CI, 4.3, na] and 26.2 [95%CI, 10.2, na] months(mo) for the 24 pts with EGFR exon20ins…